Journal of Clinical Oncology, Vol 16, 2133-2141, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

G Giaccone, TA Splinter, C Debruyne, GS Kho, P Lianes, N van Zandwijk, MC Pennucci, G Scagliotti, J van Meerbeeck, Q van Hoesel, D Curran, T Sahmoud and PE Postmus
Division of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. g.giaccone@azvu.nl

PURPOSE: To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 332 patients with advanced NSCLC were randomized to receive cisplatin 80 mg/m2 on day 1 either in combination with teniposide 100 mg/m2 on days 1, 3, and 5 (arm A) or paclitaxel 175 mg/m2 by 3-hour infusion on day 1 (arm B); cycles were repeated every 3 weeks. RESULTS: Fifteen patients were ineligible; patient characteristics were well balanced between the two arms: 71% were male, 71% had less than 5% weight loss, 89% had a World Health Organization (WHO) performance status of 0 to 1, 51% had adenocarcinoma, and 61% had stage IV disease. Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays. There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B. In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B. The frequency and severity of other toxicities were comparable between the two arms. Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018). There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B. Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively. Selected centers participated in a quality-of-life (QoL) assessment, which was performed by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and LC-13 administered at baseline and every 6 weeks thereafter. Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks. In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL. CONCLUSION: Although survival was not improved, arm B offers a better palliation for advanced NSCLC patients than arm A.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]

				R. M. Huber, M. Reck, H. Gosse, J. von Pawel, J. Mezger, J. G. Saal, R. Kleinschmidt, C. Steppert, and H. Steppling Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Eur. Respir. J., June 1, 2006; 27(6): 1183 - 1189. [Abstract] [Full Text] [PDF]

				C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Eur. Respir. J., May 1, 2006; 27(5): 895 - 901. [Abstract] [Full Text] [PDF]

				T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597. [Abstract] [Full Text] [PDF]

				C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al. Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975 J. Clin. Oncol., November 1, 2003; 21(21): 3909 - 3917. [Abstract] [Full Text] [PDF]

				V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell, C. Vadell, I. Bover, A. Ruiz-Casado, P. Azagra, U. Jimenez, et al. Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial J. Clin. Oncol., September 1, 2003; 21(17): 3207 - 3213. [Abstract] [Full Text] [PDF]

				A. Bottomley, F. Efficace, R. Thomas, V. Vanvoorden, and S. H. Ahmedzai Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials J. Clin. Oncol., August 1, 2003; 21(15): 2982 - 2992. [Abstract] [Full Text] [PDF]

				B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer Oncologist, June 1, 2003; 8(3): 270 - 277. [Abstract] [Full Text] [PDF]

				M Cullen Lung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginning Thorax, April 1, 2003; 58(4): 352 - 356. [Abstract] [Full Text] [PDF]

				M. J. Millward, M. J. Boyer, M. Lehnert, S. Clarke, D. Rischin, B.-C. Goh, J. Wong, E. McNeil, and J. F. Bishop Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients Ann. Onc., March 1, 2003; 14(3): 449 - 454. [Abstract] [Full Text] [PDF]

				E. F. Smit, K. Mattson, J. von Pawel, C. Manegold, S. Clarke, and P. E. Postmus ALIMTA(R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study Ann. Onc., March 1, 2003; 14(3): 455 - 460. [Abstract] [Full Text] [PDF]

				M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 226S - 243S. [Abstract] [Full Text] [PDF]

				G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, et al. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 1, 2002; 20(21): 4285 - 4291. [Abstract] [Full Text] [PDF]

				E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431 J. Clin. Oncol., October 15, 2002; 20(20): 4191 - 4198. [Abstract] [Full Text] [PDF]

				R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann. Onc., October 1, 2002; 13(10): 1539 - 1549. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why? J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567. [Full Text] [PDF]

				J. D. Hainsworth, J. R. Gray, L. H. Morrissey, L. A. Kalman, J. K. Hon, and F. A. Greco Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network J. Clin. Oncol., July 1, 2002; 20(13): 2937 - 2942. [Abstract] [Full Text] [PDF]

				J. P. Sculier, J. J. Lafitte, J. Lecomte, T. Berghmans, J. Thiriaux, M. C. Florin, A. Efremidis, C. G. Alexopoulos, P. Recloux, V. Ninane, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer Ann. Onc., June 1, 2002; 13(6): 874 - 882. [Abstract] [Full Text] [PDF]

				M. A. Socinski, M. J. Schell, A. Peterman, K. Bakri, S. Yates, R. Gitten, P. Unger, J. Lee, J.-H. Lee, M. Tynan, et al. Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1335 - 1343. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, R.-P. Perng, Y.-C. Lee, J.-F. Shih, C.-S. Lee, C.-M. Tsai, and J. Whang-Peng Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Ann. Onc., January 1, 2002; 13(1): 108 - 115. [Abstract] [Full Text] [PDF]

				A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax, January 1, 2002; 57(1): 20 - 28. [Abstract] [Full Text] [PDF]

				P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al. A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3942 - 3949. [Abstract] [Full Text] [PDF]

				A. Inoue and N. Saijo Recent Advances in the Chemotherapy of Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 299 - 304. [Abstract] [Full Text] [PDF]

				T. Kurata, T. Tamura, T. Shinkai, Y. Ohe, H. Kunitoh, T. Kodama, R. Kakinuma, T. Matsumoto, K. Kubota, H. Omatsu, et al. Phase I and Pharmacological Study of Paclitaxel Given Over 3 h with Cisplatin for Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., March 1, 2001; 31(3): 93 - 99. [Abstract] [Full Text] [PDF]

				I. E. Smith, M. E.R. O'Brien, D. C. Talbot, M. C. Nicolson, J. L. Mansi, T. F. Hickish, A. Norton, and S. Ashley Duration of Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin J. Clin. Oncol., March 1, 2001; 19(5): 1336 - 1343. [Abstract] [Full Text] [PDF]

				J. Cortes, J. Rodriguez, E. Calvo, F. A. Greco, H. Shigemitsu, W. G. Kuschner, S. M. Keller, and D. H. Johnson Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer N. Engl. J. Med., March 1, 2001; 344(9): 689 - 690. [Full Text] [PDF]

				M. H. Jagasia, C. J. Langer, D. H. Johnson, F. Yunus, J. S. Rodgers, L. L. Schlabach, A. G. Cohen, Y. Shyr, D. P. Carbone, and R. F. DeVore Weekly Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicenter Phase II Study Clin. Cancer Res., January 1, 2001; 7(1): 68 - 73. [Abstract] [Full Text]

				F. A. Shepherd Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Modest Progress, Many Choices J. Clin. Oncol., November 1, 2000; 18(90001): 35s - 38. [Full Text] [PDF]

				U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399. [Abstract] [Full Text] [PDF]

				O. S. Breathnach, M. S. Georgiadis, B. S. Schuler, P. Pizzella, V. Llorens, V. Kasturi, S. M. Steinberg, K. O’Neil, C. H. Takimoto, and B. E. Johnson Phase II Trial of Paclitaxel by 96-Hour Continuous Infusion in Combination with Cisplatin for Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2670 - 2676. [Abstract] [Full Text]

				P. Comella, G. Frasci, N. Panza, L. Manzione, G. De Cataldis, R. Cioffi, L. Maiorino, E. Micillo, V. Lorusso, G. Di Rienzo, et al. Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group J. Clin. Oncol., April 7, 2000; 18(7): 1451 - 1457. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and K. Kelly New Combinations in the Treatment of Lung Cancer : A Time for Optimism Chest, April 1, 2000; 117 (2009): 138S - 143S. [Abstract] [Full Text] [PDF]

				P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial J. Clin. Oncol., February 1, 2000; 18(3): 623 - 623. [Abstract] [Full Text] [PDF]

				G. Frasci, N. Panza, G. Comella, and G. Pacilio Is There Any Impact of New Drugs on the Outcome of Advanced NSCLC? An Overview of the Southern Italy Cooperative Oncology Group Trials Oncologist, October 1, 1999; 4(5): 379 - 385. [Abstract] [Full Text]

				G. Frasci, N. Panza, P. Comella, G. P. Nicolella, M. Natale, L. Manzione, D. Bilancia, R. Cioffi, L. Maiorino, G. De Cataldis, et al. Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study J. Clin. Oncol., August 1, 1999; 17(8): 2316 - 2316. [Abstract] [Full Text] [PDF]

				C. Sauter, A. J. Wozniak, and G. Giaccone Chemotherapy of Advanced Non–Small-Cell Lung Cancer: ""Those Who Cannot Remember the Past Are Condemned to Repeat It"" J. Clin. Oncol., February 1, 1999; 17(2): 730 - 730. [Full Text] [PDF]